iLite Type I IFN Assay Ready Cells
IFN Assay Ready Cells Developed and Manufactured by Svar Life Science
The Eagle Biosciences iLite Type IIFN Assay Ready Cells are intended for:
- Quantification of interferon alpha or beta activity
- Determination of Interferon alpha or beta NAbs
Content: iLite® Type I IFN Assay Ready Cells 1 vial (2.5mL)
Alternative Names: Type I Interferon Assay Ready Cells
For Research Use Only
Key benefits of iLite® Assays
- Highly specific reporter gene cell lines
- Very sensitive cell line responses (>10 fold inductions)
- Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
- Assays within a workday (typically 4-7 hour assays)
- Normalization gene, which eliminates unwanted matrix effects
In this product, human cells (U937, ATCC# CRL1593.2) engineered to express Firefly Luciferase under the control of an IFN α/β responsive promoter. When IFNα or IFNβ binds to the IFN α/β receptor on the cell surface, the IFN α/β regulated Firefly Luciferase reporter gene construct will be activated, resulting in a luminescent signal.
Interferon alpha (IFNα) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia and cutaneous T-cell lymphoma. Several different recombinant preparations of IFNα are available commercially; the most commonly used formulations include IFNα2a and IFNα2b. A number of studies have shown that development of anti-IFNα neutralizing antibodies (NAbs) is correlated with a loss of IFNα treatment efficacy. Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.